Authors

Latest:

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Hussein A. Tawbi, MD, PhD, University of Texas MD Anderson Cancer Center

Hussein A. Tawbi, MD, University of Texas MD Anderson Cancer Center

Hussein Aoun, MD

Latest:

Dr. Aoun on Imaging Modalities in Prostate Cancer

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

Hussein Tawbi, MD, PhD, UT MD Anderson Cancer Center

Hye Sook Chon, MD

Latest:

Dr Chon on Durvalumab Plus Chemotherapy and Olaparib in Endometrial Cancer

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

Hyman B. Muss, MD

Latest:

Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Hyun C. Chung, MD, PhD

Latest:

Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric Cancer

Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.

Hyung L. Kim, MD

Latest:

Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCC

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.

I. Alex Bowman, MD

I. Alex Bowman, MD is a Genitourinary Medical Oncologist at the Banner Gateway Medical Center in Gilbert, AZ.

Latest:

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Iain Tatt, PhD

Latest:

Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Ian Chau, MD

Latest:

Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Ian Chau, MD, Royal Marsden Hospital

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Ian Davis, MBBS, PhD, FRACP, FAChPM

Latest:

Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Ian E. Krop, MD, PhD

Ian E. Krop, MD, PhD, is the director of the Clinical Trials Office, as well as chief clinical research officer and associate director of Clinical Sciences at Yale Cancer Center.

Latest:

Dr Krop on Zanidatamab Plus Evorpacept in HER2+ Metastatic Breast Cancer

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Ian Flinn, MD

Latest:

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Ian Flinn, MD, PhD

Latest:

Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLL

Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Latest:

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

Ian Flinn, MD, Sarah Cannon Research Institute

Latest:

Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Ian Ganly, MD, PhD

Latest:

Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTC

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.